Furthermore, evidence on tumor-specific CD4+ and CD8+ T-cell responses and the upregulation of the IFN signature was documented, even with small numbers of administered pDCs in the range of 0.3–3 million cells per dose [29]. Here, CD8A is linked to neoplasm.